Table 2 Outcomes of GPRC5D-targeted clinical trials in MM
Author | Agent | Clinical Trial Identifier | Patients (n) | Medium number of prior LOT | Prior BCMA directed therapy | ORR |  ≥ CR | ORR in patients with Prior BCMA directed therapy | Grade ≥ 3 CRS | Grade ≥ 3 ICANS | On-target/off-tumor | Nail disorders | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sham Mailankody et al. | MCARH109 | NCT04555551 | 17 | 6 | 59% | 71% | 35% | 70% | 6% | 6% | – | 65% | [2] |
Jieyun Xia et al. | GPRC5D CAR-T | ChiCTR2100048888 | 33 | 4 | 27% | 91% | 64% | 100% | 0% | 3% | – | 27% | [3] |
Mingming Zhang et al. | OriCAR-017 | NCT05016778 | 10 | 5.5 | 50% | 100% | 60% | 100% | 0% | 0% | – | 30% | [4] |
Susan Bal et al. | BMS-986393 | NCT04674813 | 17 | 4 | 41% | 86% | – | 67% | 0% | 0% | 29% | 12% | [5] |
Ajai Chari et al. | Tal (JNJ-64407564) | NCT03399799/NCT04634552 | 0.4 mg/kg weekly:143; 0.8 mg/kg biweekly:145 | 5 | – | 0.4 mg/kg weekly:73%; 0.8 mg/kg biweekly:74% | 0.4 mg/kg weekly:29% | – | 0.4 mg/kg weekly:2%; 0.8 mg/kg biweekly:1% | – | – | 0.4 mg/kg weekly:52%; 0.8 mg/kg biweekly:43% | [6] |
Carmelo Carlo-Stella et al. | RG6234 | NCT04557150 | IV: 51; SC: 54 | IV: 5; SC: 4 | IV: 19.6%; SC: 20.4% | IV: 71.4%; SC: 60.4% | IV: 28.5%; SC: 18.8% | 55.6% | IV: 2.0%; SC: 1.9% | 1.90% | IV: 72.5%; SC: 81.5% (cutaneous AEs) | IV: 17.6%; SC: 22.2%, (hair and nail changes) | [9] |